CA1114379A — Piperidino-phthalazines
Assigned to Pfizer Corp SRL · Expires 1981-12-15 · 44y expired
What this patent protects
Abstract The invention relates to new phthalazines of the formula and the pharmaceutically acceptable salts thereof, wherein R is lower alkyl and Y is attached to the 3- or 4- position of the piperidino ring and represents a group of the formula -X-(CHR1)m-Z wherein R1 is hydro…
USPTO Abstract
Abstract The invention relates to new phthalazines of the formula and the pharmaceutically acceptable salts thereof, wherein R is lower alkyl and Y is attached to the 3- or 4- position of the piperidino ring and represents a group of the formula -X-(CHR1)m-Z wherein R1 is hydrogen or lower alkyl, m is 1 or 2 (when m is 2, each R1 may be the same or different), X is oxygen or a direct link (when m is l, X is a direct link), and Z is selected from -N(R2))COR3 -N(R2)SO2R3 -N(R2)CON4R5 and -N(R2)COOR3 where R2 is hydrogen or alkyl; R3 is alkyl, phenethyl, benzyl, phenyl or pyridyl; R4 and R5 are each hydrogen or a group as defined for R3. Several pro-cesses for preparing same are described. The new compounds are phosphodi-esterase inhibitors and cardiac stimulants.
Drugs covered by this patent
- Trulance (PLECANATIDE) · Salix
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.